

Volume - 11

No. 3

March-2018

ISSN: 0972-8988

EISSN: 2231-0916



NAAS Rating : 5.71

Indexed in ESCI-Thomson Reuters, PubMed,  
PubMed Central, DOAJ, Scopus, CABI, CAS etc.

---

---

# Veterinary World

Open access and peer reviewed journal

---

---



**Editorial office**

Veterinary World,  
Star, Gulshan Park,  
NH-8A, Chandrapur Road,  
Wankaner - 363621,  
Dist. Morbi, Gujarat, India  
Website: [www.veterinaryworld.org](http://www.veterinaryworld.org)  
E-mail: [editorveterinaryworld@gmail.com](mailto:editorveterinaryworld@gmail.com)

# Veterinary World

**Editorial Office:** Veterinary World, Star, Gulshan Park, NH-8A, Chandrapur Road, Wankaner - 363621, Dist. Morbi, Gujarat, India

ISSN: 0972-8988, EISSN: 2231-0916, [www.veterinaryworld.org](http://www.veterinaryworld.org)

## Editor-in-Chief

Anjum V. Sherasiya - Ex-Veterinary Officer, Department of Animal Husbandry, Gujarat State, India

## Associate Editors

Shambhunath Choudhary - Department of Biomedical & Diagnostic Sciences, College of Veterinary Medicine, The University of Tennessee, 2407 River Drive, Room A 201, Knoxville, TN 37996, U.S.A.

Suresh H. Basagoudanavar - FMD Vaccine Research Laboratory, IVRI, Bangalore, Bangalore- 560024, Karnataka, India

## Editorial board

R. G. Jani - Ex-Coordinator Wildlife Health, Western Region Centre, Indo-US Project, Department of Veterinary Medicine, Veterinary College, Anand - 388001, Gujarat, India

G. N. Gongal - Technical Officer, WHO South-East Asia Regional Office, New Delhi -110002, India

Ranganath Mamidi - Dr. Julian E Stelzer's Lab, Department of Physiology & Biophysics, Medical School, Case Western Reserve University, Cleveland, OH - 44106, U.S.A.

Md. Tanvir Rahman - Department of Microbiology and Hygiene, Faculty of Veterinary Science, Bangladesh Agricultural University, Mymensingh-2202, Bangladesh

Deepmala Agarwal - Cancer Prevention Laboratory, Pennington Biomedical Research Center, Baton Rouge, LA, U.S.A.

Foud Kasim Mohammad - Professor, Department of Pharmacology & Toxicology, Vice President for Administrative & Financial Affairs, University of Mosul, P.O. Box 11136, Mosul, Iraq

Abdel-Baset Nasr Sayed Ahmed - Professor and Head, Department of Animal Nutrition and Clinical Nutrition, Faculty of Veterinary Medicine, Assiut University, Assiut, Egypt

Nicole Borel - Department of Pathology, Vetsuisse Faculty, University of Zurich, CH-8057 Zürich, Switzerland

B. A. Lubisi - Virology, MED Programme, ARC - Onderstepoort Veterinary Institute, No. 100 Old Soutpan Road, Onderstepoort, Tshwane, 0110, South Africa

Kumar Venkitanarayan - Associate Professor, Graduate Programs Chair, Honors and Pre-Vet Programs Advisor, Department of Animal Science, University of Connecticut, Storrs, CT 06269, U.S.A.

Kemin Xu - Department of Veterinary Medicine, University of Maryland, College Park College Park, MD, 20742, U.S.A.

Vassilis Papatsiros - Faculty of Veterinary Medicine, Department of Medicine (Porcine Medicine), University of Thessaly, Thessaly, Greece

Mathias Devreese - Laboratory of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Ghent University, Belgium

Sumeet Sharma - Edmonton North Animal Hospital, Edmonton, Alberta, T5X 3Y7, Canada

K. P. Singh - School of Medicine and Dentistry, University of Rochester, Department of Environmental Medicine, Room: 4- 6820, 601 Elmwood Avenue, Box-EHSC, Rochester, New York-14620, U.S.A.

Raj Mohan Raja Muthiah - Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, U.S.A.

Ashok K. Chockalingam - Division of Applied Regulatory Science, U.S. Food and Drug Administration, 10903, New Hampshire Avenue, Silver Spring, Maryland 20993, U.S.A.

Ashutosh Wadhwa - Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, Mail Stop G33, Atlanta, GA 30 333, U.S.A.

Luiz Otavio Pereira Carvalho - Laboratory of Immunomodulation and Protozoology, Oswaldo Cruz Institute, Ministry of Health (Brazil), Pavilhão "108" - Sala: 09, Av. Brasil, 4365 - Manguinhos, Rio de Janeiro - RJ, CEP: 21040-360, Brazil.

Mallikarjun Bidarimath - Cornell Stem Cell Program, Department of Biomedical Sciences, T2-012 Veterinary Research Tower, Cornell University, College of Veterinary Medicine, Ithaca, NY 14853-6401, USA.

**Ratings of Veterinary World:** NAAS - National Academy of Agricultural Sciences - 5.71, Scimago Journal Rank -0.284, Citescore - 0.57, SNIP - Source Normalized Impact per Paper - 0.570

## Indexing and abstracting

Academic Journals Database, AGORA, AGRICOLA, AGRIS, CABI, CAS, DOAJ, EBSCO, EMBASE, ESCI - Thomson Reuters, Gale, Google Scholar, HINARI, Indian Animal Science Abstracts, Indian Science Abstracts, JournalSeek, Open J-gate, ProQuest, PubMed, PubMed Central, SCOPUS, TEAL

## Publisher: Veterinary World

Veterinary World is an open access journal, each issue available free of cost at [www.veterinaryworld.org](http://www.veterinaryworld.org).

We accept online submission only. For more information regarding submission and publication charges, please visit [www.veterinaryworld.org](http://www.veterinaryworld.org)

**Rs.7000 for Indian/USD 175 for Abroad per copy**

Printed and Published by Dr. Anjum V. Sherasiya on behalf of Veterinary World. Printed and Published at Star, Gulshan Park, N.H. 8A, Chandrapur Road, Wankaner-363621, Dist. Morbi, Gujarat, India.  
Editor: Dr. Anjum V. Sherasiya

---

# Veterinary World

---

ISSN: 0972-8988, EISSN: 2231-0916, [www.veterinaryworld.org](http://www.veterinaryworld.org)

---

**Volume-11**

**No.3**

**March-2018**

---

The articles in Veterinary World are open access articles licensed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

---

Research (Published online: 02-03-2018)

1. Modeling the potential risk factors of bovine viral diarrhea prevalence in Egypt using univariable and multivariable logistic regression analyses

Abdelfattah M. Selim, Mahmoud M. Elhaig, Sherif A. Moawad and Ehab El-Nahas  
Veterinary World, 11(3): 259-267

Research (Published online: 03-03-2018)

2. Semi-nested polymerase chain reaction-based detection of Babesia spp. in small ruminants from Northwest of Iran

Ahad Bazmani, Amir Abolhooshyar, Abbas Imani-Baran and Hamid Akbari  
Veterinary World, 11(3): 268-273

Research (Published online: 04-03-2018)

3. Prevailing practices in the use of antibiotics by dairy farmers in Eastern Haryana region of India

Vikash Kumar and Jancy Gupta  
Veterinary World, 11(3): 274-280

Research (Published online: 05-03-2018)

4. Prevalence of American foulbrood in asymptomatic apiaries of Kurdistan, Iran

M. Khezri, M. Moharrami, H. Modirrousta, M. Torkaman, B. Rokhzad and H. Khanbabaie  
Veterinary World, 11(3): 281-285

Research (Published online: 06-03-2018)

5. Androctonus genus species in arid regions: Ecological niche models, geographical distributions, and envenomation risk

Moulay Abdelmonaim El Hidan, Oulaid Touloun, Abdellah Bouazza, Mehdi Ait Laaradia and Ali Boumezzough  
Veterinary World, 11(3): 286-292

Research (Published online: 12-03-2018)

6. Giardiasis: Serum antibodies and coproantigens in brown rats (*Rattus norvegicus*) from Grenada, West Indies

Keshaw Tiwari, Camille Coomansingh Springer, Alfred Chikweto, Josephine Tang, Yvette Sepulveda, Amanda Leigh Smith, Nia Rametta and Ravindra Nath Sharma  
Veterinary World, 11(3): 293-296

Research (Published online: 13-03-2018)

7. Meta-analysis of classical swine fever prevalence in pigs in India: A 5-year study

S. S. Patil, K. P. Suresh, S. Saha, A. Prajapati, D. Hemadri and P. Roy  
Veterinary World, 11(3): 297-303

Research (Published online: 14-03-2018)

8. Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in *Apis mellifera* Lawang propolis extract gel-treated traumatic ulcers in diabetic rats

Diah Savitri Ernawati and Ade Puspa Sari  
Veterinary World, 11(3): 304-309

Research (Published online: 14-03-2018)

9. Three Strigeid cercariae from *Littorina littorea* snail, Qarun Lake, Fayoum, Egypt

Fayez A. Bakry, Marwa Th. Atwa and Marwa M. Attia  
Veterinary World, 11(3): 310-315

Research (Published online: 16-03-2018)

10. Prevalence and characterization of Pantone-Valentine leukocidin-positive *Staphylococcus aureus* in bovine milk in Jabalpur district of Madhya Pradesh, India

Neeraj Shrivastava, Varsha Sharma, Arpita Shrivastav, Anju Nayak and Ajay Kumar Rai  
Veterinary World, 11(3): 316-320

---

---

Research (Published online: 17-03-2018)

11. The activity of pomegranate extract standardized 40% ellagic acid during the healing process of incision wounds in albino rats (*Rattus norvegicus*)

Wiwik Misaco Yuniarti, Hardany Primarizky and Bambang Sektiari Lukiswanto  
Veterinary World, 11(3): 321-326

Research (Published online: 17-03-2018)

12. Serum cortisol level and survival rate of juvenile *Epinephelus fuscoguttatus* following exposure to different salinities

Diyana Tahir, M. Shariff, Fadhil Syukri and F. M. Yusoff  
Veterinary World, 11(3): 327-331

Research (Published online: 19-03-2018)

13. Status of theileriosis among herbivores in Iran: A systematic review and meta-analysis

Masoud Soosaraei, Mousa Motavalli Haghi, Fariborz Etemadifar, Mahdi Fakhar, Saeed Hosseini Teshnizi, Hajar Ziaei Hezarjaribi and Shabnam Asfaram  
Veterinary World, 11(3): 332-341

Research (Published online: 20-03-2018)

14. Antibacterial activity of fig leaf (*Ficus carica* Linn.) extract against *Enterococcus faecalis* and its cytotoxicity effects on fibroblast cells

Intan Nirwana, Devi Rianti, R. Helal Soekartono, Rr. Dwi Listyorini and Desi Putri Basuki  
Veterinary World, 11(3): 342-347

Research (Published online: 21-03-2018)

15. Virulence gene profiling of porcine *Pasteurella multocida* isolates of Assam

L. Babita Devi, Durlav Prasad Bora, S. K. Das, R. K. Sharma, S. Mukherjee and R. A. Hazarika  
Veterinary World, 11(3): 348-354

Research (Published online: 26-03-2018)

16. Isolation and identification of bacteria causing mastitis in small ruminants and their susceptibility to antibiotics, honey, essential oils, and plant extracts

Abeer Mostafa Abdalhamed, Gamil Sayed Gamil Zeedan and Hala Abdoula Ahmed Abou Zeina  
Veterinary World, 11(3): 355-362

Research (Published online: 26-03-2018)

17. Detection of *Brucella* spp. in milk from seronegative cows by real-time polymerase chain reaction in the region of Batna, Algeria

Rabehi Sabrina, Hamdi Taha Mossadak, Marnache Bakir, Meghezzi Asma and Boushaba Khaoula  
Veterinary World, 11(3): 363-367

Research (Published online: 27-03-2018)

18. Evaluation of antimycobacterial activity of *Curcuma xanthorrhiza* ethanolic extract against *Mycobacterium tuberculosis* H37Rv in vitro

Ngadino, Setiawan, Koerniasari, Ernawati and S. A. Sudjarwo  
Veterinary World, 11(3): 368-372

Research (Published online: 27-03-2018)

19. Antibacterial and antioxidant activity of *Juniperus thurifera* L. leaf extracts growing in East of Algeria

Merradi Manel, Heleili Nouzha, Mekari Rim, Mekkaoui Imane, Aouachria Sana, Oucheriah Yasmine and Ayachi Ammar  
Veterinary World, 11(3): 373-378

Research (Published online: 28-03-2018)

20. Isolation of Shiga toxin-producing *Escherichia coli* harboring variant Shiga toxin genes from seafood

Sreepriya Prakasan, Parmanand Prabhakar, Manjusha Lekshmi, Binaya Bhusan Nayak and Sanath Kumar  
Veterinary World, 11(3): 379-385

Research (Published online: 30-03-2018)

21. Inventory of lice of mammals and farmyard chicken in North-eastern Algeria

Mohamed Nadir Meguini, Souad Righi, Faycal Zeroual, Khelaf Saidani and Ahmed Benakhla  
Veterinary World, 11(3): 386-396

Research (Published online: 31-03-2018)

22. ISMap02 element targeted nested polymerase chain in the detection of *Mycobacterium avium* subsp. *paratuberculosis* in fecal samples of cattle and buffaloes

Mamta Rani, Deepti Narang, Dinesh Kumar, Mudit Chandra, Sikh Tejinder Singh and G. Folia  
Veterinary World, 11(3): 397-401

\*\*\*\*\*

## The activity of pomegranate extract standardized 40% ellagic acid during the healing process of incision wounds in albino rats (*Rattus norvegicus*)

Wiwik Misaco Yuniarti, Hardany Primarizky and Bambang Sektiari Lukiswanto

Department of Veterinary Clinical Science, Faculty of Veterinary Medicine, Universitas Airlangga, Mulyorejo, Campus C Unair, Surabaya, 60115, Indonesia.

**Corresponding author:** Hardany Primarizky, e-mail: [kikken.zeyra@gmail.com](mailto:kikken.zeyra@gmail.com)

**Co-authors:** WMY: [wiwikmisaco@yahoo.com](mailto:wiwikmisaco@yahoo.com), BSL: [bamsekti@yahoo.com](mailto:bamsekti@yahoo.com)

**Received:** 17-11-2017, **Accepted:** 06-02-2018, **Published online:** 17-03-2018

**doi:** 10.14202/vetworld.2018.321-326 **How to cite this article:** Yuniarti WM, Primarizky H, Lukiswanto BS (2018) The activity of pomegranate extract standardized 40% ellagic acid during the healing process of incision wounds in albino rats (*Rattus norvegicus*), *Veterinary World*, 11(3): 321-326.

### Abstract

**Aim:** This research aimed to evaluate the effects of pomegranate extract standardized to 40% ellagic acid on the incised wound in albino rats.

**Materials and Methods:** Fifty albino rats were divided into 10 treatment groups. The five groups were sacrificed on the 8<sup>th</sup> day, while the others were sacrificed on the 15<sup>th</sup> day. Two groups of albino rats with incised wound were not treated at all (P0), the other two groups of albino rats with incised wound were treated with Betadine® (P1) ointment, and the rest of the groups were treated with pomegranate extract standardized to 40% ellagic acid with a concentration of 2.5% (P2), 5% (P3), and 7.5% (P4). The treatments were carried out twice a day with an interval of 12 h for 7 and 14 days. At the end of the research, the skin tissue of those albino rats had been taken for histopathologic preparations before H and E staining was performed.

**Results:** Collagen deposition, polymorphonuclear neutrophils (PMN) infiltration, angiogenesis, and fibrosis degree in Group P4 treated with 7.5% pomegranate extract standardized to 40% ellagic acid for 14 days were significantly different from those in Groups P0, P1, P2, and P3, especially in the case of PMN inflammation ( $p < 0.05$ ).

**Conclusion:** The administration of 7.5% pomegranate extract standardized to 40% ellagic acid for 14 days on incised wounds of those albino rats can accelerate the wound healing process characterized by collagen deposition improvement, PMN infiltration in the wound area, angiogenesis, and fibrosis degree.

**Keywords:** albino rats, ellagic acid, incision wound, pomegranate, wound healing process.

### Introduction

Wound healing process is a complex phenomenon to restore the continuity of tissues and their function. Wound healing process involves several distinct and overlapping phases, namely, inflammatory phase, granulation phase, fibrogenesis phase, neovascularization phase, wound contraction phase, and epithelialization phase [1]. Effective wound management, as a result, requires an understanding of the normal wound healing process as well as is expected to be able to choose the right interventions to optimize the wound healing process [2].

Inflammation, moreover, occurs immediately after the injury, started with vasoconstriction that plays a role in triggering hemostasis process and releasing inflammatory mediators. Next, the proliferative phase is characterized by the formation of granulation tissue by fibroblasts and angiogenesis processes.

Reformulation and repair of collagen fiber compartments accompanied by increased tensile strength then indicate remodeling phase [3]. However, there are several factors inhibiting wound healing process, such as recurrent trauma, poor perfusion, and oxygenation, as well as excessive inflammation [4].

Therefore, natural ingredients are considered as an essential part of health management and a good method for providing a cheap and effective health-care option, especially for wound treatment [5,6]. For instance, *Punica granatum* Linn. (Punicaceae), commonly called as pomegranate, a shrub from the Mediterranean [7,8], has been proven by several previous researches as good medicine for wound healing process [5,6,8]. Pomegranate fruit and flowers even have been widely used by the public for treating gastritis, gastrointestinal infections, gastrointestinal bleeding, dysentery, and various types of wounds [8,9].

Pomegranate, furthermore, has been known to have antitumor, antidiarrheal, antiulcer, antifungal, antioxidant, and hepatoprotector activities [7,10]. Pomegranate extract is also widely used for the treatment of diabetes mellitus and bacterial infection [11,12]. Some previous researchers even have proven that pomegranate extract contains polyphenol compounds, namely, ellagic acid, 3,3', 4'-tri-O-methyl ellagic acid, ethyl

Copyright: Yuniarti, et al. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

brevifolin carboxylate, maslinic acid, daucosterol, and tannin [13,14]. Ellagic acid has antioxidant and anti-inflammatory activity through free radical scavenging, regulation of phase 1 and 1 enzymes, modulates the secretion of proinflammatory and profibrotic cytokines and regulates the biochemical pathways that involved in lipid synthesis and degradation during inflammation [15]. Previous studies have been reported the compounds that responsible for antioxidant, anti-inflammatory, and antibacterial activities. Tannins, which consisted of punicallin, punicalagin, pedunculagin, gallic acid, and casuarinin are responsible as antioxidant. The ellagic acid, gallic acid, punicalagin, granatin, and gallagylidilactone are compounds that have anti-inflammatory effect. Catechin, epicatechin, epigallocatechin-3-gallate, flavan-3-ol, kaempferol, and quercetin are compounds that have antibacterial activity and have reported also as an antioxidant, anti-inflammatory, antiviral and anti-neoplastic [16-18]. Unfortunately, there was still a lack of researchers on the potency of pomegranate extract standardized to 40% ellagic acid for wound healing. Thus, this research aimed to reveal the effects of pomegranate extract standardized to 40% ellagic acid as a regulator of incised wound healing process in albino rats as experimental animals.

## Materials and Methods

### Ethical approval

This research has been approved by the ethical commission of Faculty of Dental Medicine, Universitas Airlangga, with Ethical Clearance Certificate's Number 108/HRECC.FODM/VII/2017.

### Experimental animals

In this research, 50 healthy male albino rats (*Rattus norvegicus*) aged 3 months old and weighed 150-180 g were used as experimental animals.

### Research materials

Materials used in this research were whole fruit extract of pomegranate (*P. granatum* Linn.) standardized with 40% ellagic acid produced by Xi'an Bio-Technology Co., Ltd., Betadine® (PT One Med), Ketamin® (PT Guardian Pharmatama), diazepam, vaseline flavum, 70% ethanol, 10% formalin buffer, alcohol at various concentrations, pellet, and sterile aquadest. This research also used some materials for making preparations of histopathological examination using hematoxylin-eosin (HE) staining technique.

### Research tools

Research tools used were some surgical tools for making incised wounds and removing skin tissue, such as gloves, scissors, sterile cotton, plastic spoon, cotton bud, tweezers, clamp arteries, scalpel number 3, ruler, Hypafix, blade number 10, and razor blade. This research also used pots to place the skins that had been excised.

Besides, mortar and stamper were used in this research for making ointments. Some tools for making histopathology preparations, such as microtome and

embedding set, glass object, glass cover, staining set, as well as microscope were also used.

### Treatment

Fifty male albino rats (*R. norvegicus*) were adapted first for 1 week. During the adaptation period, they were fed with sufficient food and drink. They also got several health examinations and treatments.

After the adaptation period, rats then were randomly divided into 10 treatment groups with five different treatments. Variables then observed were histopathologic images of those albino rats' incised skin (*R. norvegicus*).

The use of pure ellagic acid (100%) for topical administration on infected wounds that infected with *Staphylococcus aureus* showed that 1% concentration gave the best results in accelerating the process of wound healing [19]. Based on that research, the topical ointment preparations, 2.5, 5, and 7.5% of pomegranate extract that standardized 40% of ellagic acid were used in this study (ellagic acid content in each dosage is 1, 2, and 3%).

Treatments administrated in this research were as follows:

P0.1:	Incised wounds without any treatment and observed on day 8
P0.2:	Incised wounds without any treatment and observed on day 15
P1.1:	Incised wounds treated with Betadine® and observed on day 8
P1.2:	Incised wounds treated with Betadine® and observed on day 15
P2.1:	Incised wounds treated with 2.5% pomegranate extract ointment standardized to 40% ellagic acid and then observed on day 8
P2.2:	Incised wounds treated with 2.5% pomegranate extract ointment standardized to 40% ellagic acid and then observed on day 15
P3.1:	Incised wounds treated with 5% pomegranate extract ointment standardized to 40% ellagic acid and then observed on day 8
P3.2:	Incised wounds treated with 5% pomegranate extract ointment standardized to 40% ellagic acid and then observed on day 15
P4.1:	Incised wounds treated with 7.5% pomegranate extract ointment standardized to 40% ellagic acid and then observed on day 8
P4.2:	Incised wounds treated with 7.5% pomegranate extract ointment standardized to 40% ellagic acid and then observed on day 15

In all groups, except for Group P0.1 and P0.2, those rats were shaved off in their paravertebral area of 3 cm×2.5 cm to facilitate the incision process. At the time of making the wound, those rats were anesthetized in advance with a combination of ketamine and diazepam (100 mg/ml: 5 mg/ml) at a dose of 1 ml/kg of body weight [20]. The incision then was carried straight toward the caudals along 3 cm, 0.25 cm deep, and 0.01 cm wide in the area that had been shaved [21].

Next, certain treatments were given topically by applying Betadine® ointment for certain groups, and pomegranate extract ointment standardized to 40%

ellagic acid for some other groups with a cotton bud. Those treatments were performed twice in a day with an interval of 12 h for 7 and 14 days [22].

Afterward, skin tissue and blood of those albino rats were taken after they were sacrificed using ether per inhalation. The skin tissue was taken with a scalpel at a depth of 0.5 cm and over 1 cm from the right, left, top, and bottom sides of the incised wound to make histopathologic preparations.

### Observation

The histologic criteria for skin preparation were defined as follows:

1. Collagen was indicated with score 2 for a normal bundle of collagen, score 1 for unorganized/edema of collagen, and score 0 for amorphous one
2. Polymorphonuclear neutrophils (PMN) was indicated with score 2 for a PMN cell count of 0-10, score 1 for a PMN cell count of 11-40, and score 0 for a PMN cell count of >40
3. Angiogenesis was categorized into three degrees, namely, mild, moderate, and severe
4. Fibrosis degree was indicated by measuring the thickness of collagen bundles, divided into three, namely, mild, moderate, and severe [23].

### Statistical analysis

All data of skin histopathology examination were analyzed by a statistical test according to the data type obtained. Mean values were compared using the Kruskal–Wallis test. If treatment had led to a marked difference, it would have continued with a further statistical test to measure the differences between the groups. *Post hoc* analysis was performed using Mann–Whitney U-test. In this case, the significance level was set at 5%. As a result, which treatment gave the best result could be determined.

### Results


In this research, evaluation was performed on the histopathologic preparations that had been made on microscopic images by scoring collagen, PMN, angiogenesis, and fibrosis degree in each treatment group on days 8 and 15.

On day 8, there was a relatively similar microscopic image in all treatment groups. The results of the evaluation showed the deposition of amorphous collagen was found in Group P0 and P1 (Figure-1a and b), while the deposition of disorganized collagen was found in Group P2, P3, and P4 (Figure-1c-e). The results also indicated that PMN cell count in all treatment groups was above 40. In addition, the degree of angiogenesis ranged from mild in Group P0 (Figure-1a) to moderate one in Group P1, P2, P3, and P4 (Figure-1b-e). Fibrosis, on the other hand, was dominated by mild degree, such as in Group P0, P1, P2, and P3 (Figure-2a-d), whereas Group P4 had moderate fibrosis (Figure-2e). Besides, the results of the statistical analysis demonstrated that there was no significant difference between Group P4 on day 8 and Groups P2

and P3 on the same day ( $p > 0.05$ ). However, there was a significant difference between Group P4 on day 8 and Groups P0 and P1 ( $p < 0.05$ ) on the same day (Table-1).

The results of the observation on day 15 showed a slightly different pattern. The collagen deposition found dominantly was in the disorganized form, such as in Group P1, P2, P3, and P4 (Figure-2b-e). Meanwhile, the amorphous one was only found in Group P0 (Figure-2a). The results also indicated that the PMN cell count in all treatment groups was still above 40 (Figure-2a-d), except in Group P4 (Figure-2e). Moreover, the degree of angiogenesis in all treatment groups was known to be dominated with mild degree. On the other hand, the fibrosis degree was dominated by severe ones such as in Group P0, P1, and P2 (Figure-2a-c). Meanwhile, the moderate fibrosis degree was only found in Group P1 and P4 (Figure-2d and e).

Furthermore, the results of the statistical analysis revealed that Group P4 was not significantly different from Group P2 ( $p > 0.05$ ). However, there was a significant difference between Group P4 and Group P0, P1, as well as P3 ( $p > 0.05$ ) (Table-2).



**Figure-1:** Histopathological images of those albino rats' skin on each treatment on day 8 (H and E, 100×, [a] P0, [b] P1, [c] P2, [d] P3, [e] P4). P0 - Amorphous collagen (arrow black), PMN >40 cells (green arrow), mild angiogenesis (orange arrow), and mild fibrosis degree (blue arrow). P1 - Amorphous collagen (arrow black), PMN >40 cells (green arrow), moderate angiogenesis (orange arrow), and mild fibrosis (blue arrow). P2 - Disorganized collagen (black arrow), PMN >40 cells (green arrow), moderate angiogenesis (orange arrow), and mild fibrosis (blue arrow). P3 - Disorganized collagen (black arrow), PMN >40 cells (green arrow), moderate angiogenesis (orange arrow), and mild fibrosis (blue arrow). P4 - Disorganized collagen (black arrow), PMN >40 cells (green arrow), moderate angiogenesis (orange arrow), and moderate fibrosis (blue arrow).

The provision of 7.5% pomegranate extract standardized to 40% ellagic acid for 14 days gave the best result in accelerating the healing process of incised wound in those albino rats (Table-3).

## Discussion

In this research, the efficacy of pomegranate extract ointment standardized to 40% ellagic acid for healing incised wounds in the albino rats was evaluated. The results showed that the observation and treatment periods can significantly influence the wound healing process characterized by collagen deposition, PMN, angiogenesis, and fibrosis degree. The results of the research indicated that 7.5% pomegranate extract ointment standardized to 40% ellagic acid could more effectively regulate the wound healing process if given 14 days than Betadine ointment as well as 2.5% and 5% pomegranate extract ointment standardized to 40% ellagic acid. Thus, in Group P4 the provision of the extract for 14 days was able to repair incised wounds with histopathologic features close to normal skin composition. The condition was characterized by well-organized and unorganized deposits, a PMN count of <40, light angiogenesis, as well as moderate fibrosis degree.

The results of the treatment scoring showed that Group P4 observed for 14 days got optimal result compared to the histopathology of normal skin since on day 14, proliferation and remodeling processes

will continue for 21 days [24]. In this research, the administration of 7.5% pomegranate extract standardized to 40% ellagic acid was also known to be able to regulate the healing process by increasing collagen production, decreasing PMN cell infiltration, and increasing angiogenesis. The time required for the process is also shorter than the other treatment groups.

Pomegranates have been known to have various pharmacological activities, such as anti-inflammatory [25], antioxidant [26], antibacterial [27], antifungal [28], antispasmodic [29], antiulcer [30], and anticancer activities [31] as well as accelerate wound healing process [7]. A previous research even argues that pomegranates contain ellagic acid, tannins, and other compounds. Tannins and ellagic acids have antibacterial activity, thus accelerating the wound healing process. Unfortunately, its mechanism is still unclear. As a result, in this research the existence of these compounds was expected can accelerate the healing process of incised wound [13]. Pure ellagic acid (100%) has antioxidant, anti-inflammatory, and antibacterial activity. When the ellagic acid 40% of pomegranate extract was used in this study, it means that there are 40% of ellagic acid and 60% of non-ellagic acid content. When the dosages used were equivalent to the most optimal dosage of pure ellagic acid (100%) are showed better results, then the strong suspicion that

**Table-1:** Comparison of the wound healing process on day 8.

Treatment groups	Deposition	PMN	Angiogenesis degree	Fibrosis degree
P0	0.0 <sup>a</sup> ±0.00	0.0 <sup>a</sup> ±0.00	0.8 <sup>a</sup> ±0.45	0.8 <sup>a</sup> ±0.45
P1	0.2 <sup>a</sup> ±0.45	0.0 <sup>a</sup> ±0.00	2.0 <sup>b</sup> ±0.00	1.2 <sup>ab</sup> ±0.45
P2	1.0 <sup>b</sup> ±0.00	0.2 <sup>ab</sup> ±0.45	2.2 <sup>b</sup> ±0.45	1.8 <sup>bc</sup> ±0.45
P3	0.6 <sup>ab</sup> ±0.90	0.4 <sup>ab</sup> ±0.90	1.4 <sup>ab</sup> ±0.55	2.6 <sup>c</sup> ±0.55
P4	1.4 <sup>b</sup> ±0.55	0.8 <sup>b</sup> ±0.45	2.4 <sup>b</sup> ±0.55	2.4 <sup>c</sup> ±0.45

Score values were presented in the mean±SD. Different superscripts on the same polymer showed a significant difference ( $p < 0.05$ ). SD=Standard deviation, PMN=Polymorphonuclear neutrophils

**Table-2:** Comparison of the wound healing process on day 15.


Treatment groups	Deposition	PMN	Angiogenesis degree	Fibrosis degree
P0	0.6 <sup>ab</sup> ±0.55	0.0 <sup>a</sup> ±0.00	1.0 <sup>a</sup> ±0.00	3.0 <sup>a</sup> ±0.00
P1	1.0 <sup>ab</sup> ±0.00	0.2 <sup>a</sup> ±0.45	1.6 <sup>ab</sup> ±0.55	3.0 <sup>a</sup> ±0.00
P2	0.8 <sup>ab</sup> ±0.45	0.6 <sup>ab</sup> ±0.55	1.2 <sup>ab</sup> ±0.45	2.8 <sup>a</sup> ±0.45
P3	0.4 <sup>a</sup> ±0.55	0.2 <sup>a</sup> ±0.45	1.6 <sup>ab</sup> ±0.55	3.0 <sup>a</sup> ±0.00
P4	1.6 <sup>b</sup> ±0.55	1.4 <sup>b</sup> ±0.55	1.8 <sup>b</sup> ±0.45	2.6 <sup>a</sup> ±0.55

Score values were presented in the mean±SD. Different superscripts on the same polymer showed a significant difference ( $p < 0.05$ ). SD=Standard deviation, PMN=Polymorphonuclear neutrophils

**Table-3:** Comparison of the wound healing process on day 8 and 15.

Treatment groups	Deposition		PMN		Angiogenesis degree		Fibrosis degree	
	Day 8	Day 15	Day 8	Day 15	Day 8	Day 15	Day 8	Day 15
P0	0.0 <sup>a</sup> ±0.00	0.6 <sup>a</sup> ±0.55	0.0 <sup>a</sup> ±0.00	0.0 <sup>a</sup> ±0.00	0.8 <sup>a</sup> ±0.45	1.0 <sup>a</sup> ±0.00	0.8 <sup>a</sup> ±0.45	3.0 <sup>b</sup> ±0.00
P1	0.2 <sup>a</sup> ±0.45	1.0 <sup>b</sup> ±0.00	0.0 <sup>a</sup> ±0.00	0.2 <sup>ab</sup> ±0.45	2.0 <sup>b</sup> ±0.00	1.6 <sup>ab</sup> ±0.55	1.2 <sup>c</sup> ±0.45	3.0 <sup>b</sup> ±0.00
P2	1.0 <sup>ab</sup> ±0.00	0.8 <sup>b</sup> ±0.45	0.2 <sup>a</sup> ±0.45	0.6 <sup>ab</sup> ±0.55	2.2 <sup>b</sup> ±0.45	1.2 <sup>a</sup> ±0.45	1.8 <sup>c</sup> ±0.45	2.8 <sup>b</sup> ±0.45
P3	0.6 <sup>ab</sup> ±0.90	0.4 <sup>a</sup> ±0.55	0.4 <sup>ab</sup> ±0.90	0.2 <sup>ab</sup> ±0.45	1.4 <sup>ab</sup> ±0.55	1.6 <sup>ab</sup> ±0.55	2.6 <sup>b</sup> ±0.55	3.0 <sup>b</sup> ±0.00
P4	1.4 <sup>ab</sup> ±0.55	1.6 <sup>b</sup> ±0.55	0.8 <sup>b</sup> ±0.45	1.4 <sup>b</sup> ±0.55	2.4 <sup>b</sup> ±0.55	1.8 <sup>b</sup> ±0.45	2.4 <sup>b</sup> ±0.45	2.6 <sup>bc</sup> ±0.55

Score values were presented in the mean±SD. Different superscripts on the same polymer showed a significant difference ( $p < 0.05$ ). SD=Standard deviation, PMN=Polymorphonuclear neutrophils



**Figure-2:** Histopathological images of those albino rat's skin in each treatment group on day 15 (H and E, 100×, day 15 [a] P0, [b] P1, [c] P2, [d] P3, [e] P4). P1 - Disorganized collagen (black arrow), PMN >40 cells (green arrow), mild angiogenesis (orange arrow), and severe fibrosis (blue arrow). P2 - Amorphous collagen (black arrow), PMN >40 cells (green arrow), mild angiogenesis (orange arrow), and moderate fibrosis (blue arrow). P3 - Disorganized collagen (black arrow), PMN >40 cells (green arrow), mild angiogenesis (orange arrow), and severe fibrosis (blue arrow). P4 - Disorganized collagen (black arrow), PMN <40 cells (green arrow), mild angiogenesis (orange arrow), and moderate fibrosis (blue arrow).

there is synergism of various materials that contained in pomegranate extract standardized 40%, so it also generates stronger effect [16].

In general, wound healing process can be divided into three different phases, namely, inflammatory phase, proliferation phase, and remodeling phase. Inflammation phase is characterized by the accumulation of inflammatory cells (PMN) in the wound area. The proliferative process, on the other hand, will be accompanied by epithelialization, angiogenesis, and collagen formation. Fibroblasts, collagen, edema, and new blood vessels then will soon form and get undergo maturation in the next remodeling phase. Collagen is indispensable for maintaining tissue strength in the wound area [32].

In other words, the provision of 7.5% pomegranate extracts standardized to 40% ellagic acid could accelerate the healing process of the incised wound in those rats compared to other treatment groups since pomegranate has antioxidant, anti-inflammatory, and antibacterial activities. These three activities will be synergized in the process of wound healing.

## Conclusion

The administration of 7.5% pomegranate extract standardized to 40% ellagic acid for 14 days on incised

wounds of those albino rats can accelerate the wound healing process characterized by collagen deposition improvement, PMN infiltration in wound area, angiogenesis, and fibrosis degree.

## Authors' Contributions

WMY, BSL, and HP are designed the concept for this research and scientific paper. WMY and HP have conducted the research work, e.g., maintenance of animal laboratory, collecting samples, compiling the resource materials and did the laboratory work. WMY and BSL were provided technical supports and analyzed data. All authors participated in manuscript's draft and revision. All authors have read and approved the final manuscript.

## Acknowledgments

The authors gratefully acknowledge the support from Faculty of Dental Medicine, Faculty of Pharmacy and Veterinary Teaching Hospital, Universitas Airlangga, Surabaya, Indonesia, for providing facilities to conduct the research. All authors are also thankful to Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya, Indonesia, for financial support with Grant Number: 56/UN3.1.6/2017.

## Competing Interests

The authors declared that they have no competing interests.

## References

1. Robson, M.C. (1997) Wound infection: A failure of wound healing caused by an imbalance of bacteria. *Surg. Clin.*, 77: 637-650.
2. Snyder, R.J. (2005) Treatment of nonhealing ulcers with allografts. *Clin. Dermatol.*, 23: 388-395.
3. Varoglu, E., Seven, B., Gumustekin, K., Aktas, O., Sahin, A. and Dane, S. (2010) The effects of vitamin E and selenium on blood flow to experimental skin burns in rats using the <sup>133</sup>Xe clearance technique. *Cent. Eur. J. Med.*, 5: 219-223.
4. Harding, G., Moore, K. and Phillips, T.J. (2005) Wound chronicity and fibroblast senescence-implications for treatment. *Int. Wound J.*, 2: 364-368.
5. Suntar, I.P., Akkol, E.K. and Yilmazer, D. (2010) Investigations on the *in vivo* wound healing potential of *Hypericum perforatum* L. *J. Ethnopharmacol.*, 127: 468-477.
6. Gurung, S. and Skalko-Basnet, N. (2009) Wound healing properties of *Carica papaya* latex: *In vivo* evaluation in mice burn model. *J. Ethnopharmacol.*, 121: 338-341.
7. Kaur, G., Jabbar, Z., Athar, M. and Alam, M.S. (2006) *Punica granatum* (Pomegranate) flower extract possesses potent antioxidant activity and abrogates Fe-NTA induced hepatotoxicity in mice. *Food Chem. Toxicol.*, 44: 984-993.
8. Momen-Tonkaboni, S.M. (2008) *Tohfatul-Momenin (Tohfehe-Hakim Momen)*, Traditional Medicine of Research center of Shahid Beheshti University of Medical Sciences. Nashre Shar Constitute, Tehran, Iran.
9. Al Yahya, M.A. (2005) Preliminary phytochemical and pharmacological and on the rind of pomegranate (*Punica granatum* L.). *Pak. J. Biol. Sci.*, 8: 479-481.
10. Arun, N. and Singh, D. (2012) *Punica granatum*: A review on pharmacological and therapeutic properties. *Int. J. Pharm. Sci. Res.*, 2: 1240-1245.
11. Reddy, M.K., Gupta, S.K., Jacob, M.R., Khan, S.I. and Ferreira, D. (2007) Antioxidant, antimalarial and

- antimicrobial activities of tannin-rich fractions, ellagitannins and phenolic acids from *Punica granatum* L. *Planta Med.*, 73: 461-467.
12. Fernando, L.A.F., Silva, K.R.D. and Lopes, A.P. (2014) Preclinical evaluation of the crude extract from the fruits of *Punica granatum* L. (Punicaceae) for antimicrobial activity in *in vitro* and *ex vivo* experimental models: A comparative study. *Afr. J. Pharm. Pharmacol.*, 8: 479-484.
  13. Ghosh, P.K. and Gaba, A. (2013) Phyto-extracts in wound healing. *J. Pharm. Pharm. Sci.*, 16: 760-820.
  14. Pirbalouti, A.G., Shahrzad, A., Abed, K. and Hamed, B. (2010) Wound healing activity of *Malva sylvestris* and *Punica granatum* in alloxan-induced diabetic rats. *Acta Pol. Pharm.*, 67: 511-516.
  15. Garcia-Nino, W.R. and Zazueta, C. (2015) Review ellagic acid: Pharmacological activities and molecular mechanisms involved in liver protection. *Pharmacol. Res.*, 97: 84-103.
  16. Malviya, S., Jha, A.A. and Hettiarachchy, N. (2014) Antioxidant and antibacterial potential of pomegranate peel extracts. *J. Food Sci. Technol.*, 51: 4132-4137.
  17. Nono, R.N., Barboni, L., Teponno, R.B., Quassinti, L., Bramucci, M., Vitali, L.A., Petrelli, D., Lupidi, G. and Tapondjou, A.L. (2014) Antimicrobial, antioxidant, anti-inflammatory activities and phytoconstituents of extracts from the roots of *Dissotis thollonii* Cogn. (*Melastomataceae*). *South Afr. J. Bot.*, 93: 19-26.
  18. Han, D.H., Lee, M.J. and Kim, J.H. (2006) Antioxidant and apoptosis-inducing activities of ellagic acid. *Anticancer Res.*, 26: 3601-3606.
  19. Wandari, A. (2014) Effect of Topical Ellagic acid to the Healing Process of Wound Incision of Rats (*Rattus norvegicus*) Infected with *Staphylococcus aureus*. Thesis. Faculty of Veterinary Medicine. Universitas Airlangga. Surabaya, Indonesia.
  20. Yuniarti, W.M. (2012) Anti-fibrotic Effect of Pomegranate Extract (*Punica granatum* L.) on liver fibrosis. Dissertation. Faculty of Medicine. Universitas Airlangga. Surabaya, Indonesia.
  21. Murthy, S., Gautam, M.K., Goel, S., Purohit, V., Sharma, H. and Goel, R.K. (2013) Evaluation of *in vivo* wound healing activity of *Bacopa monniera* on different wound model in rats. *Biomed. Res. Int.*, 2013: 1-9.
  22. Alizadeh, A.M., Sohanaki, H., Khaniki, M., Mohaghheghi, M.A., Ghmami, G. and Mosavi, M. (2011) The effect of *Teucrium polium* honey on the wound healing and tensile strength in rat. *Iran. J. Basic Med. Sci.*, 14: 499-505.
  23. Kulac, M., Aktas, A., Tulubas, A., Uygur, R., Kanter, M., Erboga, M., Ceber, M., Topcu, B. and Ozen, O.A. (2012) The effects of topical treatment with curcumin on burn wound healing in rats. *J. Mol. Histol.*, 44: 83-90.
  24. Castelli Von, A.D.A.N., Gragnani, A., Francescato, V.D., Felipe, A.L.E., Felix, C.L.L., Ricardo, T., dos Anjos, M.A.R. and Masako, F.L. (2013) Unripe *Musa sapientum* peel in the healing of surgical wounds in rats. *Acta Cir. Bras.*, 28: 1-8.
  25. Sarker, M., Das, S.C., Saha, S.K., Al Mahmud, Z. and Bachar, S.C. (2012) Analgesic and anti-inflammatory activities of flower extracts of *Punica granatum* Linn. (Punicaceae). *J. App. Pharm. Sci.*, 2: 133-136.
  26. Singh, R.P., Chidambara, M.K.N. and Jayaprakasha, G.K. (2002) Studies on the antioxidant activity of pomegranate (*Punica granatum*) peel and seed extracts using *in vitro* models. *J. Agric. Food Chem.*, 50: 81-86.
  27. Hassanzadeh, G., Hajmanouchehri, F., Roi, A.B., Hassanzadeh, N., Shafiqh, N., Barzroudi, M., Baazm, M. and Choobineh, H. (2013) Comparing effects of silver sulfadiazine, sucralfate and *Brassica oleracea* extract on burn wound healing. *Life Sci. J.*, 10: 852-861.
  28. Pirbalouti, A.G., Koohpayeh, A. and Karimi, I. (2010) The wound healing activity of flower extracts of *Punica granatum* and *Achillea kellarensis* in wistar rats. *Acta Pol. Pharm.*, 67: 107-110.
  29. Ahangarpour, A., Heidari, R., Abdolazadeh, M. and Oroojan, A.A. (2012) Antispasmodic effects of aqueous and hydroalcoholic *Punica granatum* flower extracts on the uterus of non-pregnant rats. *J. Reprod. Infertil.*, 13: 140-142.
  30. Gautam, R. and Sharma, S.C. (2012) Anti-ulcer activity of *Punica granatum* Linn. in diabetic rats. *Int. J. Pharm. Pharm. Sci.*, 4: 459-461.
  31. Lansky, E.P. and Newman, R.A. (2007) *Punica granatum* (pomegranate) and its potential for prevention and treatment of inflammation and cancer. *J. Ethnopharmacol.*, 109: 177-206.
  32. Perini, J.A., Angeli-Gamba, T., Alessandra-Perini, J., Claudio Ferreira, L., Eurico, N.L. and Escorsim, M.D. (2015) Topical application of achesflan on rat skin injury accelerates wound healing: A histopathological, immunohistochemical and biochemical study. *BMC Compl. Altern Med.*, 15: 203-210.

\*\*\*\*\*